Suchergebnisse - (Subject:"Humans")

PubPharm (412)

1

Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1

enthalten in: Bulletin du cancer | 2024

von Lévêque, I. | Spitzer, E.

2

Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours

enthalten in: Bulletin du cancer | 2024

von Croce, S. | Devouassoux-Shisheboran, M. | Pautier, P. | +17

3

Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic

enthalten in: Bulletin du cancer | 2023

von Noé, C. | Edeline, J.

4

Prognostic value of residual disease detection in acute myeloid leukemia with normal karyotype and negative FLT3-ITD

enthalten in: Annales de biologie clinique | 2023

von Jaddaoui, S. | Bencharef, H. | Addakiri, S. | +4

5

Drug approval : ATEZOLIZUMAB as monotherapy in NSCLC PD-L1 ≥ 50%, without EGFR mutation or ALK rearrangement, for adjuvant treatment after complete surgery and platinum-based chemotherapy

enthalten in: Bulletin du cancer | 2023

von Boudier, B. | Aldea, M.

6

Co-administration of pertuzumab and trastuzumab is practical in home hospitalization

enthalten in: Bulletin du cancer | 2023

von Pailler, C. | Gandrille, N. | Poterre, M. | +2

7

Management of EGFR mutated non-small cell lung carcinoma patients

enthalten in: Revue des maladies respiratoires | 2022

von Perquis, M. | Tissot, C. | Bouleftour, W. | +4

8

Myeloid neoplasms associated with rearrangement of PDGFRB : A rare and tricky disease

enthalten in: Annales de pathologie | 2022

von Bontoux, C. | Badaoui, B. | Abermil, N. | +13

9

Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021

enthalten in: Bulletin du cancer | 2022

von Mezni, E. | Sabatier, R. | Goncalves, A. | +1

10

New EMA drug approval : Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)

enthalten in: Bulletin du cancer | 2022

von Quesada, S. | Vaflard, P.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[42]